Talphera Inc. (TLPH) - Total Liabilities

Latest as of September 2025: $11.56 Million USD

Based on the latest financial reports, Talphera Inc. (TLPH) has total liabilities worth $11.56 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Talphera Inc. (TLPH) cash flow conversion to assess how effectively this company generates cash.

Talphera Inc. - Total Liabilities Trend (2008–2024)

This chart illustrates how Talphera Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check TLPH asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Talphera Inc. Competitors by Total Liabilities

The table below lists competitors of Talphera Inc. ranked by their total liabilities.

Company Country Total Liabilities
GFG Resources Inc
V:GFG
Canada CA$2.27 Million
Nusa Konstruksi Enjiniring Tbk
JK:DGIK
Indonesia Rp712.04 Billion
Mondi PLC
LSE:MNDI
UK GBX4.84 Billion
Kanoria Chemicals & Industries Limited
NSE:KANORICHEM
India Rs5.77 Billion
Lider Faktoring AS
IS:LIDFA
Turkey TL7.88 Billion
Doctor Care Anywhere Group Plc
AU:DOC
Australia AU$15.11 Million
Canlan Ice Sports Corp.
TO:ICE
Canada CA$80.61 Million
Panorama Sentrawisata Tbk
JK:PANR
Indonesia Rp724.87 Billion

Liability Composition Analysis (2008–2024)

This chart breaks down Talphera Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Talphera Inc. (TLPH) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.83 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.60 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.38 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Talphera Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Talphera Inc. (2008–2024)

The table below shows the annual total liabilities of Talphera Inc. from 2008 to 2024.

Year Total Liabilities Change
2024-12-31 $10.24 Million +62.72%
2023-12-31 $6.29 Million -75.50%
2022-12-31 $25.67 Million -77.44%
2021-12-31 $113.79 Million -6.77%
2020-12-31 $122.05 Million -8.08%
2019-12-31 $132.77 Million +14.18%
2018-12-31 $116.28 Million +3.76%
2017-12-31 $112.06 Million +6.39%
2016-12-31 $105.33 Million +11.26%
2015-12-31 $94.67 Million +138.11%
2014-12-31 $39.76 Million +7.83%
2013-12-31 $36.87 Million +20.21%
2012-12-31 $30.67 Million +31.27%
2011-12-31 $23.37 Million -67.87%
2010-12-31 $72.72 Million +7.76%
2009-12-31 $67.48 Million +20.48%
2008-12-31 $56.01 Million --

About Talphera Inc.

NASDAQ:TLPH USA Drug Manufacturers - Specialty & Generic
Market Cap
$42.82 Million
Market Cap Rank
#22569 Global
#4731 in USA
Share Price
$0.92
Change (1 day)
+1.06%
52-Week Range
$0.39 - $1.46
All Time High
$115.20
About

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulat… Read more